These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25284480)

  • 81. PI3-kinase mutation linked to insulin and growth factor resistance in vivo.
    Winnay JN; Solheim MH; Dirice E; Sakaguchi M; Noh HL; Kang HJ; Takahashi H; Chudasama KK; Kim JK; Molven A; Kahn CR; Njølstad PR
    J Clin Invest; 2016 Apr; 126(4):1401-12. PubMed ID: 26974159
    [TBL] [Abstract][Full Text] [Related]  

  • 82. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 83. bFGF-mediated pluripotency maintenance in human induced pluripotent stem cells is associated with NRAS-MAPK signaling.
    Haghighi F; Dahlmann J; Nakhaei-Rad S; Lang A; Kutschka I; Zenker M; Kensah G; Piekorz RP; Ahmadian MR
    Cell Commun Signal; 2018 Dec; 16(1):96. PubMed ID: 30518391
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors.
    Liu Y; Wang D; Li Z; Li X; Jin M; Jia N; Cui X; Hu G; Tang T; Yu Q
    Sci Rep; 2022 Apr; 12(1):5924. PubMed ID: 35395865
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pseudomonas aeruginosa pyocyanin activates NRF2-ARE-mediated transcriptional response via the ROS-EGFR-PI3K-AKT/MEK-ERK MAP kinase signaling in pulmonary epithelial cells.
    Xu Y; Duan C; Kuang Z; Hao Y; Jeffries JL; Lau GW
    PLoS One; 2013; 8(8):e72528. PubMed ID: 24015256
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways.
    Martínez D; Vermeulen M; Trevani A; Ceballos A; Sabatté J; Gamberale R; Alvarez ME; Salamone G; Tanos T; Coso OA; Geffner J
    J Immunol; 2006 Jan; 176(2):1163-71. PubMed ID: 16394005
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.
    Pandey SK; Théberge JF; Bernier M; Srivastava AK
    Biochemistry; 1999 Nov; 38(44):14667-75. PubMed ID: 10545192
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
    Mizoguchi M; Nutt CL; Mohapatra G; Louis DN
    Brain Pathol; 2004 Oct; 14(4):372-7. PubMed ID: 15605984
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation.
    Ghosh-Choudhury N; Mandal CC; Choudhury GG
    J Biol Chem; 2007 Feb; 282(7):4983-4993. PubMed ID: 17179158
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
    Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV).
    De Bortoli M; Queisser A; Pham VC; Dompmartin A; Helaers R; Boutry S; Claus C; De Roo AK; Hammer F; Brouillard P; Abdelilah-Seyfried S; Boon LM; Vikkula M
    J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38431221
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical phenotype of the PIK3R1-related vascular overgrowth syndrome.
    Kuentz P; Engel C; Laeng M; Chevarin M; Duffourd Y; Martel J; Piard J; Morice-Picard F; Aubert H; Bessis D; Guerrot AM; Maruani A; Boccara O; Mazereeuw-Hautier J; Ott H; Phan A; Puzenat E; Quelin C; Thauvin-Robinet C; Faivre L; Vabres P
    Br J Dermatol; 2024 Jul; 191(2):303-305. PubMed ID: 38623710
    [No Abstract]   [Full Text] [Related]  

  • 96. Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.
    Hamaguchi T; Hirota Y; Takeuchi T; Nakagawa Y; Matsuoka A; Matsumoto M; Awano H; Iijima K; Cha PC; Satake W; Toda T; Ogawa W
    J Diabetes Investig; 2018 Sep; 9(5):1224-1227. PubMed ID: 29476696
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The double life of p85.
    Costa C; Engelman JA
    Cancer Cell; 2014 Oct; 26(4):445-7. PubMed ID: 25314071
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.
    Cheung LW; Mills GB
    Pharmacogenomics; 2016 Feb; 17(3):297-307. PubMed ID: 26807692
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Systematic Functional Annotation of Somatic Mutations in Cancer.
    Ng PK; Li J; Jeong KJ; Shao S; Chen H; Tsang YH; Sengupta S; Wang Z; Bhavana VH; Tran R; Soewito S; Minussi DC; Moreno D; Kong K; Dogruluk T; Lu H; Gao J; Tokheim C; Zhou DC; Johnson AM; Zeng J; Ip CKM; Ju Z; Wester M; Yu S; Li Y; Vellano CP; Schultz N; Karchin R; Ding L; Lu Y; Cheung LWT; Chen K; Shaw KR; Meric-Bernstam F; Scott KL; Yi S; Sahni N; Liang H; Mills GB
    Cancer Cell; 2018 Mar; 33(3):450-462.e10. PubMed ID: 29533785
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
    Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.